Ipsen Upbeat Despite Palovarotene Pain
Healthy Sales Rise In 2019
The French drugmaker's current product portfolio is performing well but a €669m charge relating to the failure of palovarotene for the rare bone disease FOP blighted Ipsen's financials.
You may also be interested in...
The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.
Ipsen’s chief business officer tells Scrip that buying Canada’s Clementia Pharmaceuticals this year gave the French group’s rare disease operations an “anchor asset” to build on.
Buying Canada-based Clementia is consistent with Ipsen’s strategy to acquire top assets in mid to late stages of development for specialty oncology, neuroscience or rare disease indications, chief commercial officer tells Scrip.